ClinConnect ClinConnect Logo
Search / Trial NCT05853796

Observational Dutch Young Symptomatic StrokE studY - nEXT

Launched by RADBOUD UNIVERSITY MEDICAL CENTER · May 2, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The Dutch Young Symptomatic Stroke study, also known as nEXT, is looking at what causes strokes in young adults aged 18 to 50. Each year, around 2 million young people experience an ischemic stroke, which occurs when a blood clot blocks blood flow to the brain. The researchers want to understand the role of blood clotting, inflammation, and blood vessel health in these strokes. They are particularly interested in how certain factors, like infections or other triggers, might lead to these events and how to better prevent them in the future.

To participate in this study, you must be between 18 and 50 years old and have had your first ischemic stroke or a transient ischemic attack (TIA), which is a temporary stroke-like event. Participants will undergo tests to assess their blood clotting and inflammation levels, as well as have imaging done on a special MRI machine. The study aims to gather important information that could improve treatments and prevent future strokes in young patients. It’s a chance to contribute to research that could make a real difference for others in similar situations.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with a first-ever transient ischemic attack (TIA) or acute ischemic stroke aged between 18 and 50 years old
  • For this study, acute stroke is defined as "occurence of acute neurological deficit lasting more than 24 hours, with confirmation on imaging (CT(-a) or MR(-a))".TIA is defined as "occurence of acute neurological deficit lasting less than 24 hours with confirmation of ischemia on MRI).
  • Patients have a kidney function eGFR\>30ml/min.
  • Exclusion Criteria:
  • A history of clinical TIA, ischemic stroke or intracerebral hemorrhage
  • A intracerebral hemorrhage resulting from trauma, known aneurysm or underlying intracerebral malignancy.
  • A venous infarction, retinal infarction or amourosis fugax.
  • Inadequate control of the Dutch language to reliably sign an informed consent from and/or participate in the follow-up
  • Patients are excluded if they have a contra indication for 3T MRI.

About Radboud University Medical Center

Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.

Locations

Enschede, , Netherlands

Leeuwarden, , Netherlands

Leeuwarden, , Netherlands

Eindhoven, Noord Brabant, Netherlands

Nijmegen, , Netherlands

Zwolle, Overijssel, Netherlands

Enschede, Overijssel, Netherlands

Den Haag, Zuid Holland, Netherlands

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported